Benzinga

Benzinga

Benzinga

sábado, agosto 29

Elevance Health Inc

ELVNYSE
Trade with Public
Trade with Public
$394.43
-4.68-1.17%
al cierre: Aug 28, 5:00 PM EST
$394.30
-0.13-0.03%
After hour: 4:12 PM EST
Dividendo: La fecha límite del dividendo es dentro de 12 días
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Elevance Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Elevance Health (ELV).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

14Buy
6Hold
Consensus RatingBuy# Analysts20Avg. Consensus PT$438Upside to Avg. PT+11.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 17, 2026Leerink PartnersWhit MayoPT RaiseMarket Perform$364→$395
Jul 16, 2026RBC CapitalBen HendrixPT CutSector Perform$439→$424
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Elevance Health, Raises Price Target to $395

Leerink Partners analyst Whit Mayo maintains Elevance Health (NYSE:ELV) with a Market Perform and raises the price target from $364 to $395.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Elevance Health, Lowers Price Target to $424

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Sector Perform and lowers the price target from $439 to $424.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Elevance Health, Lowers Price Target to $473

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $492 to $473.
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Elevance Health Following Q2 Earnings

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $455

Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $399 to $455.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $457

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $480 to $457.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved